A randomised, double-blind study to evaluate the efficacy and safety of Avastin plus Roferon compared with placebo plus Roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma.

Trial Profile

A randomised, double-blind study to evaluate the efficacy and safety of Avastin plus Roferon compared with placebo plus Roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AVOREN
  • Sponsors Roche
  • Most Recent Events

    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2010 Results published in Journal of Clinical Oncology.
    • 05 Mar 2010 Results of an indirect comparison of sunitinib vs bevacizumab + interferon-alpha-2a using results from this and another phase III trial (NCT00098657) were presented at ASCO 2010 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top